Micregen has a unique understanding of how stem cells can be manipulated to produce potent stem cell secretions, known as Secretomix.
Secretomix, as a new class of patent protected products are anticipated to deliver novel regenerative therapeutic approaches which are allogeneic, scalable and have application across a wide range of diseases.
Secretomix facilitate cell repair, reduce inflammation, reduce scarring, improve blood flow and generate a pro-regenerative microenvironment across a wide range of organs and tissue types. Micregen believe that their innovative approach has the potential to change the way that multiple critical and chronic problems are managed.
This approach has been developed from the founders lifetime experience on the use of autologous stem cell secretome therapeutics in cutting-edge biological and regenerative medicine, which has already saved lives and world famous sporting careers.
Micregen’s immediate aim is to take a novel, first in class therapy MRG1061 to treat orphan neonatal conditions into clinical trials in 2024.
The long term strategic goal is to leverage Micregen's Secretomix R&D into these neonate indications and develop therapeutics for adults to enable 'healthy-ageing'.
Micregen believe that by avoiding the risks of whole cell transplant, graft versus host disease and the other challenges associated with the development of current stem cell treatments, there could be a step change in the utility of cell originated therapies.